Current Health Hunters Newsletter:

What if we had a therapy that is effective, nontoxic, and affordable, to address inflammation and autoimmune conditions? We may have the answer with a novel use of the drug Naltrexone.

This medication was synthesized in 1963 as an opioid receptor antagonist, meaning it blocks opioid receptors. It was approved in 1984 for the treatment of opioid addiction at a typical daily dose of 50-100 mg.

Low Dose Naltrexone (LDN) refers to doses of the drug Naltrexone that are 1/10th or less than the typical opioid addiction treatment dose. Taken at bedtime at the low dose level of 1.5-4.5 mg, LDN has paradoxical properties including: analgesic, immune-modulating, and anti-inflammatory effects, which are not seen at higher doses. LDN has been used clinically since the 1980’s. The first published human trial was presented in 2007, demonstrating the effectiveness of LDN in patients with fibromyalgia. At the end of the study over half of the patients receiving LDN reported feeling “much improved” or “very much improved.”